Production (Stage)
Protara Therapeutics, Inc.
TARA
$3.34
$0.2156.89%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 3.39% | 12.98% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.31% | 16.07% | |||
| Operating Income | 1.31% | -16.07% | |||
| Income Before Tax | 6.70% | -13.82% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 6.70% | -13.82% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 6.70% | -13.82% | |||
| EBIT | 1.31% | -16.07% | |||
| EBITDA | 1.33% | -16.20% | |||
| EPS Basic | 39.41% | 3.84% | |||
| Normalized Basic EPS | 39.42% | 3.85% | |||
| EPS Diluted | 39.41% | 3.84% | |||
| Normalized Diluted EPS | 39.42% | 3.85% | |||
| Average Basic Shares Outstanding | 54.01% | 18.37% | |||
| Average Diluted Shares Outstanding | 54.01% | 18.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||